<DOC>
	<DOC>NCT02669901</DOC>
	<brief_summary>The purpose of this pilot-study is to to distribute naloxone auto-injector in a "Universal Precaution" manner to patients with opioid substance use disorder. The objectives are to decrease the number of fatal and nonfatal overdose deaths, to examine and understand the risk factors for serious opioid toxicity and overdose, and to evaluate the unintentional opioid overdose risk utilizing an evidence-based screening questionnaire.</brief_summary>
	<brief_title>Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Substance Use Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Drug Overdose</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>All patients treated with methadone, naltrexone or buprenorphine as medication assisted treatment at the UNM Addiction and Substance Abuse Program (UNM ASAP) aged 18 or older Subjects who are allergic to naloxone and its inactive ingredients. Inactive ingredients include buffering agents. Subjects younger than 18. Subjects not being treated at UNM ASAP.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Opioid-Related Disorders</keyword>
	<keyword>Naloxone</keyword>
	<keyword>Harm Reduction</keyword>
	<keyword>Drug Overdose Deaths</keyword>
	<keyword>Opioid Misuse</keyword>
	<keyword>Naloxone Coprescribing</keyword>
	<keyword>Universal Precautions</keyword>
	<keyword>Opioid Substance Use Disorder</keyword>
</DOC>